Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Genprex, Inc.
  6. News
  7. Summary
    GNPX   US3724461047

GENPREX, INC.

(GNPX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Genprex : to Move Forward With Phase 1/2 Trial of Lung Cancer Combo Therapy

06/23/2021 | 10:39am EDT


© MT Newswires 2021
All news about GENPREX, INC.
07/20GENPREX : to Participate in a Monthly CEO Roadshow Webinar Series
BU
07/12GENPREX, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/28GENPREX : Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQ..
PU
06/28GENPREX, INC. : Submission of Matters to a Vote of Security Holders, Other Event..
AQ
06/25GENPREX, INC.(NASDAQCM : GNPX) dropped from Russell Small Cap Completeness Index
CI
06/25GENPREX, INC.(NASDAQCM : GNPX) dropped from Russell 3000 Index
CI
06/25GENPREX, INC.(NASDAQCM : GNPX) dropped from Russell 3000E Growth Index
CI
06/25GENPREX, INC.(NASDAQCM : GNPX) dropped from Russell 2000 Index
CI
06/25GENPREX, INC.(NASDAQCM : GNPX) dropped from Russell 3000E Index
CI
06/25GENPREX, INC.(NASDAQCM : GNPX) dropped from Russell 2500 Growth Index
CI
More news
Financials (USD)
Sales 2021 15,0 M - -
Net income 2021 -23,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -38,3x
Yield 2021 -
Capitalization 145 M 145 M -
Capi. / Sales 2021 9,66x
Capi. / Sales 2022 5,80x
Nbr of Employees 12
Free-Float 89,4%
Chart GENPREX, INC.
Duration : Period :
Genprex, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENPREX, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 3,06 $
Average target price 8,25 $
Spread / Average Target 170%
EPS Revisions
Managers and Directors
J. Rodney Varner Executive Chairman, President, CEO & Secretary
Ryan M. Confer Chief Financial Officer
Shannon Inman Vice President-Global Clinical Operations
Michael T. Redman Chief Operating Officer & Executive Vice President
Brent M. Longnecker Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GENPREX, INC.-26.27%170
GILEAD SCIENCES, INC.18.47%85 134
WUXI APPTEC CO., LTD.37.17%71 226
REGENERON PHARMACEUTICALS21.37%57 013
BIONTECH SE245.88%55 555
VERTEX PHARMACEUTICALS-15.16%50 308